Page 2 - Nuclear Export News Today

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) have been given an average recommendation of “Moderate Buy” by the five ratings firms that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month […]

NEWTON, Mass., April 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an...

Karyopharm Therapeutics Inc. (KPTI.NASDAQ): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Karyopharm Therapeutics Inc. | Nasdaq: KPTI | Nasdaq

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.15 and traded as low as $0.69. Karyopharm Therapeutics shares last traded at $0.77, with a volume of 1,320,715 shares changing hands. Wall Street Analysts Forecast Growth KPTI […]

Presenter SpeechEric Joseph Good afternoon. Im Eric Joseph, senior biotech analyst with JPMorgan. Our next presenting company is Karyopharm Therapeutics and presenting on behalf of the company to...

– Accelerating Innovation and Growth Strategy with Top-Line Data Readouts Expected in 2H 2024 and 2025 from Three Pivotal Phase 3 Studies Evaluating Selinexor in Multiple Myeloma, Endometrial...

NEWTON, Mass., Jan. 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Companys senior...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has been given an average rating of “Moderate Buy” by the six brokerages that are currently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month target price among […]

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price […]

Biomarker Data from Phase 1 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis (MF) Suggestive of Disease Modification